Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Trattamento migliorato per i pazienti con terapia con oppioidi a lungo termine per il dolore non canceroso nelle cure primarie (Opi-Prim)

25 settembre 2026 aggiornato da: Thomas Kempen, Uppsala County Council, Sweden

Trattamento migliorato per i pazienti con terapia con oppioidi a lungo termine per il dolore non canceroso nelle cure primarie (OPI-PRIM)

The goal of this clinical trial is to reduce inappropriate long term opioid treatment (LTOT) and to optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centred and team-based approach. The main question it aims to answer is:

What are the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care?

Researchers will compare a new person-centred and team-based approach to usual care to see if pain interference is lower.

Participants will receive a person-centred team-based treatment consisting of:

  • Phase 1 (investigation and assessment, week 1-3): A medication review, pain analysis and other assessments through separate visits to a pharmacist, general practitioner, physiotherapist, psychologist and care manager
  • Phase 2 (treatment plan, week 3-4): A team consultations with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made based.
  • Phase 3 (treatment and follow-up, week 4-24): Implementation of the individualized rehabilitation plan with frequent follow-up contacts (1 per 1-3 weeks) by phone with the care manager.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The evidence for prescribing opioids to patients suffering from chronic non-cancer pain is weak, and using opioids in these circumstances is questionable. Swedish primary health care is responsible for about one-third of all first-time opioid prescriptions and has the highest rate of prescription renewals for opioids. The decision for long-term opioid therapy (LTOT) should rest on an accurate pain analysis and should result in an individualized assessment where the risks of LTOT are set against the impact on quality of life that living with long-term pain entails. Multi-professional interventions and a person-centered approach are recommended for chronic non-cancer pain. Although pharmacists in primary health care have been established internationally with successful examples related to LTOT, their role in Swedish primary care and the management of chronic non-cancer pain remains to be studied. Currently, it is unclear which interventions are effective in reducing inappropriate LTOT and which alternative interventions are suitable for patients who are currently receiving LTOT. The involvement of a care manager in the patient´s care has shown promising results regarding quality of care for other long-term conditions, for example depresssion. In Region Uppsala, clinical pharmacists havte recently been employed in primary health care, but it is unclear what their tasks and responsibilities are and how to best make use of their competence. It is therefore relevant and justified to investigate a new person-centered team-based approach including care manager and pharmacist to optimize the management of pain in patients with chronic non-cancer pain in Swedish primary care. This project aims to reduce inappropriate LTOT and optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centered and team-based approach.

Primary objective:

To investigate the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care

Trial design and setting:

This study is a controlled before-and-after study that has been designed, and will be reported, according to the CONSORT guidelines. Participation will be during 52 weeks (12 months).

This study will be conducted at eight healthcare centres in Region Uppsala. At four of the healthcare centres, a new person-centred team-based treatment model including pharmacists (intervention) will be implemented. Prerequisites for these healthcare centres are the accessibility of at least one person of each healthcare profession: pharmacist, general practitioner (GP), psychologist (or social worker) and physiotherapist, where one of these (or a rehabilitation coordinator or a nurse) takes the role of care manager. Healthcare personnel will receive special training in managing patients with chronic pain before the study. In addition, four control healthcare centres without a pharmacist will be matched with the intervention healthcare centres according to geographic area (urban, suburban, rural), socioeconomical setting and the size of the centres (number of listed patients). No specific efforts of implementation will be made in these control centres.

Prior to the full trial, a feasibility study will be conducted at one intervention centre and one control centre with 12 weeks follow-up per participant.

Tipo di studio

Interventistico

Iscrizione (Stimato)

110

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Gävleborg County
      • Gävle, Gävleborg County, Svezia
        • Non ancora reclutamento
        • Region Gävleborg
        • Contatto:
    • Södermanland County
      • Strängnäs, Södermanland County, Svezia
        • Non ancora reclutamento
        • Region Sörmland
        • Contatto:
    • Uppsala County
      • Uppsala, Uppsala County, Svezia
        • Reclutamento
        • Region Uppsala
        • Contatto:
    • Örebro County
      • Örebro, Örebro County, Svezia

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 70 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Having received the equivalent of 90 days or more prescription of opioids for chronic pain made by the general practitioner during the recent 12 months
  • Able to speak Swedish or English

Exclusion Criteria:

  • Having been referred to a pain clinic (either at hospital or multimodal rehabilitation in primary care) within the last 6 months
  • No current opioid use, severe cognitive dysfunction, e.g., suicidal ideation, psychotic symptoms, or dementia, that prevents informed consent.
  • Using their opioids for cancer pain

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Control

Participants in the control healthcare centres will receive usual care. This may include appointments and treatment by a general practitioner, nurse, physiotherapist and/or psychologist. No pharmacist will be working at the healthcare centre. However, Uppsala County Council does provide centralized medication review services to all primary healthcare centres in Region Uppsala. Any healthcare professional may request a medication review by a pharmacist on a work-from-home basis as part of usual care.

Comparatore attivo: Intervention

Phase 1 (investigation and assessment, week 1-3):

  • A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist.
  • A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms.
  • A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities.
  • A visit to a psychologist for diagnostics and treatments regarding psychological and social factors.
  • A visit to a care manager

Phase 2 (treatment plan, week 3-4):

- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made.

Phase 3 (treatment and follow-up, week 4-24):

  • Implementation of the individualized rehabilitation plan.
  • Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager.
  • A second team consultation half-way

Phase 1 (investigation and assessment, week 1-3):

  • A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist.
  • A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms.
  • A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities.
  • A visit to a psychologist for diagnostics and treatments regarding psychological and social factors.
  • A visit to a care manager

Phase 2 (treatment plan, week 3-4):

- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made.

Phase 3 (treatment and follow-up, week 4-24):

  • Implementation of the individualized rehabilitation plan.
  • Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager.
  • A second team consultation half-way

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Pain interference
Lasso di tempo: The primary outcome measure will be the difference in mean pain interference after 6 months.

Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 9 a-g. Scale: 0-10. Higher score is worse.

The primary outcome measure will be the difference in mean pain interference after 6 months.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Pain intensity
Lasso di tempo: After 3, 6 and 12 months

Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 3-8. Scale: 0-10. Higher score is worse

After 3, 6 and 12 months
Symptoms of depression
Lasso di tempo: After 3, 6 and 12 months

Measured with the Patient Health Questionnaire-9 (PHQ-9). Scale: 0-27. Higher score is worse

After 3, 6 and 12 months
Symptoms of anxiety
Lasso di tempo: After 3, 6 and 12 months

Measured with the General Anxiety disorder-7 (GAD-7). Scale: 0-27. Higher score is worse

After 3, 6 and 12 months
Patient satisfaction
Lasso di tempo: After 3, 6 and 12 months

Measured with the Patients´ Global impression of Change (PGIC). Scale: 0-6. Higher score is worse

After 3, 6 and 12 months
Quality of life according to the 5-level EuroQol 5D
Lasso di tempo: After 3, 6 and 12 months

Measured with the 5-level EuroQol 5D (EQ-5D-5L). Scale: 1-5 per dimension. Higher score is worse.

After 3, 6 and 12 months
Opioid use
Lasso di tempo: After 3, 6 and 12 months

Measured with as morphine equivalents: in mg.

After 3, 6 and 12 months
Symptoms of withdrawal
Lasso di tempo: After 3, 6 and 12 months

Measured with the Short Opioid Withdrawal Scale (SOWS). Scale: 0-40. Higher score is worse

After 3, 6 and 12 months
Pain interference
Lasso di tempo: After 3 and 12 months

Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 9 a-g. Scale: 0-10. Higher score is worse.

After 3 and 12 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

10 marzo 2025

Completamento primario (Stimato)

30 giugno 2028

Completamento dello studio (Stimato)

31 dicembre 2028

Date di iscrizione allo studio

Primo inviato

26 febbraio 2025

Primo inviato che soddisfa i criteri di controllo qualità

26 febbraio 2025

Primo Inserito (Effettivo)

4 marzo 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

30 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

25 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • Opi-Prim

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .